Share on LinkedInShare on LinkedIn

ARTICLE · 17 DECEMBER 2003

Valley Drug Co. v. Geneva Pharmaceuticals, Inc.

A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that were seeking FDA approval of a drug patented by the name brand manufacturer.

United StatesAntitrust/Competition Law

Article by Mr John North and Mr William L. Warren

A recent 11th Circuit case, Valley Drug Co. v. Geneva Pharmaceuticals, Inc., sheds light on the complex intersection of patent and antitrust law in the context of a settlement agreement between a name brand pharmaceutical manufacturer and two allegedly infringing generic manufacturers that were seeking FDA approval of a drug patented by the name brand manufacturer.1 The plaintiffs in this case claimed that the settlement agreements constituted a horizontal contract in restraint of trade in violation of Section 1 of the Sherman Act.2 The district court agreed, granting the plaintiffs’ motion for partial summary judgment on the basis that the agreements were per se anticompetitive. On appeal, the 11th Circuit reversed. It held that such settlement agreements must be analyzed to determine whether the agreements exceed the patentee’s right to exclude others from making, using, or selling the patented subject matter. If the agreements

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from